Project Grant R21CA294050
Award Date
6/1/24
Completion Date
5/31/26
Dollars Obligated
$405K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
This $142,295 Project Grant was awarded on May 1, 2025 by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) federal grant program. The grant will fund research to identify gut microbial and metabolomic biomarkers associated with the relationship between ultra-processed foods and colorectal cancer risk, as well as evaluate the feasibility and initial efficacy of a medically tailored meal intervention to improve survivorship among colorectal cancer patients. The...
This Project Grant award of $400,890, provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research), supports research to profile patient-specific tumor-microbiome interactions and conduct molecular analyses to elucidate microbiome-mediated modulation of immune checkpoint molecules in mismatch repair-proficient, microsatellite-stable colorectal tumors. The research team at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University will utilize...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), aims to develop an intervention against colorectal cancer (CRC) associated with colibactin-producing bacteria. The $627,422 award to the Regents of the University of Michigan will fund research to engineer E. coli bacteria to display an enzyme that neutralizes the carcinogenic colibactin toxin. The project will optimize the surface display of this anti-toxin...
This $372,142 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports research at the University of South Carolina to investigate the impact of early life exposure to antibiotics on the risk of early onset colorectal cancer (EOCRC). The key objectives are to: 1) identify developmental windows of susceptibility to antibiotics, and 2) determine if antibiotic-induced dysbiosis drives EOCRC. The project...
This $678,399 Project Grant award was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program to The University of Texas MD Anderson Cancer Center. The funding will support a research study to evaluate the impact of a prebiotic diet intervention combined with standard immune checkpoint inhibitor (ICI) therapy in patients with metastatic melanoma.
The study aims to investigate whether the prebiotic diet intervention can modulate the...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $697,763 to The University of Texas MD Anderson Cancer Center to investigate the genetic determinants that allow the bacterium Fusobacterium nucleatum (F. nucleatum) to selectively colonize colorectal cancer (CRC) tumors. The research aims to elucidate the mechanisms by which F. nucleatum, a member of the oral microbiome, is able to persist within the CRC tumor microenvironment...
This federal Project Grant award of $192,610 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) aims to evaluate the impact of social determinants of health (SDOH) on early-onset colorectal cancer (EOCRC) outcomes in Kentucky and Georgia. The primary objectives are to examine the relationships between SDOH factors (e.g., economic stability, education, healthcare access, neighborhood environment, social context) and EOCRC diagnosis,...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will support a 5-year, $600,499 research project titled "Microbial and Host Biomarkers in Colorectal Cancer Oncogenesis" at The Trustees of Columbia University in the City of New York. The key objectives are to investigate the role of the oral bacterium Fusobacterium nucleatum and its amyloid-like adhesin FadA in colorectal cancer growth, as well as the involvement of...
This $1,355,273 Project Grant was awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) to the Regents of the University of Michigan. The grant funds the development of two complementary approaches to inhibit the production of the bacterial metabolite colibactin, which has been linked to colorectal cancer and microbiome dysbiosis.
The first approach involves enzymatic inactivation of colibactin through...
This $460,985 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) aims to develop a novel therapeutic strategy to target liver metastasis in colon cancer patients. The primary objectives are to:
Determine the therapeutic efficacy of selective dopamine D4 receptor (DRD4) agonists, either alone or in combination with anti-cancer drugs, to prevent or lower the incidence of liver metastasis in preclinical animal models simulating...